From: Pathological transition as the arising mechanism for drug resistance in lung cancer
Patient ID | Gender | Age | Smoking status | Therapy | 1st biopsya | 2nd biopsyb | References | ||
---|---|---|---|---|---|---|---|---|---|
Pathological status | Mutation status | Pathological status | Mutation status | ||||||
1 | F | 79 | N | Chemotherapy | ADC | EGFR 19 del | SCC | EGFR 19 del | [112] |
2 | M | 43 | Y | Chemotherapy | ADC | EGFR 19 del | SCC | EGFR 19 del | [113] |
3 | F | 48 | N | Gef | ADC | EGFR 19 del | SCC | EGFR 19 del | [114] |
4 | F | 51 | NA | Gef | ADC | EGFR 19 del | SCC | EGFR 19 del | [115] |
5 | F | 58 | Y | Erl | ADC | EGFR 19 del | SCC | EGFR 19 del | [116] |
6 | F | 66 | N | Erl | ADC | EGFR 19 del | SCC | EGFR 19 del | [117] |
7 | F | 67 | NA | Afa | ADC | EGFR 19 del | SCC | EGFR 19 del and PIK3CA mutation | [118] |
8 | F | 40 | Y | Afa | ADC | EGFR 19 del | SCC | EGFR 19 del + T790M | [119] |
9 | F | 79 | N | Gef | ADC | EGFR 19 del | SCC | EGFR L858R + T790M | [120] |
10 | M | 41 | Y | Gef | ADC | EGFR 19 del | SCC + SCLC | NA | [61] |
11 | F | 52 | Y | Erl + Beva | ADC | EGFR 19 del | SCC | EGFR 19 del | [121] |
12 | F | 61 | N | Gef | ADC | EGFR L858R | SCC | EGFR L858R | [115] |
13 | M | 62 | N | Gef | ADC | EGFR L858R | SCC | EGFR L858R | [122] |
14 | F | 63 | N | Erl | ADC | EGFR L858R | SCC | EGFR L858R and PIK3CA | [123] |
15 | F | 74 | Y | Gef | ADC | EGFR L858R | SCC | EGFR L858R + T790M | [120] |
16 | M | 68 | Y | Erl | ADC | EGFR L858R | SCC | EGFR L858R + T790M | [124] |
17 | F | 43 | Y | Gef | ADC | EGFR L858R | SCC | EGFR L858R +S768I | [125] |
18 | F | 64 | N | Gef | ADC | EGFR L858R + T790M | SCC | EGFR L858R + T790M | [114] |
19 | F | 60 | Y | ALK TKI | ADC | ALK | SCC | ALK | [126] |
20 | F | 52 | N | Crizo/Alec | ADC | ALK | SCC | ALK | [127] |
21 | F | 63 | N | Erl | ADC | WT | SCC | EGFR L858R + T790M | [128] |
22 | M | 69 | N | Chemotherapy–immunotherapy | ADC | WT | SCC | NA | [129] |